Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited (ZURA) is a clinical-stage biotechnology company advancing novel therapies for immune and inflammatory disorders, with its lead candidate zb-168 targeting IL7rα pathways. This page serves as the definitive source for verified company news and developments.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection ensures access to essential updates while maintaining scientific accuracy and regulatory compliance.
Key content includes phase trial results, research collaborations, and mechanism-of-action studies related to zb-168's potential in treating alopecia areata and other immune-mediated conditions. All materials are vetted for relevance to therapeutic development timelines.
Bookmark this page for streamlined access to Zura Bio's latest scientific advancements and corporate announcements. Regularly updated to reflect material developments in immune modulation research.
Zura Bio Limited (Nasdaq: ZURA) has licensed tibulizumab, an anti-IL-17 and anti-BAFF dual antagonist, from Eli Lilly. The compound will be designated as ZB-106 and has already undergone two Phase 1b studies demonstrating an acceptable safety profile. Zura plans to initiate a Phase 2 study for ZB-106 in Systemic Sclerosis in 2024. Additionally, the company has announced a private placement financing to raise approximately $80 million, selling around 18.8 million Class A ordinary shares and pre-funded warrants. The financing is expected to enhance Zura’s cash reserves to approximately $120 million, sufficient to fund operations through 2026. The offering is led by multiple investment firms, and shares are priced at $4.25.
Zura Bio Limited (Nasdaq: ZURA) has appointed Michael D. Howell, Ph.D., as the new Chief Scientific Officer and Head of Translational Science. With over two decades of experience, Dr. Howell will spearhead the scientific strategy and translational research efforts at Zura Bio. Prior to this role, he was a scientific advisor during the company's formation in 2022. His extensive background includes leadership positions at DermTech, Incyte Corporation, and AstraZeneca. Zura Bio focuses on developing therapies for immune and inflammatory disorders and is advancing its pipeline, including Phase 2 programs like ZB-168 and torudokimab. CEO Someit Sidhu expressed confidence in Dr. Howell's expertise to drive the company’s science and clinical development forward.
FAQ
What is the current stock price of Zura Bio (ZURA)?
What is the market cap of Zura Bio (ZURA)?
